Changes in Susceptibility to Oncolytic Vesicular Stomatitis Virus during Progression of Prostate Cancer

Journal of Virology
Nanmeng YuDouglas S Lyles

Abstract

A major challenge to oncolytic virus therapy is that individual cancers vary in their sensitivity to oncolytic viruses, even when these cancers arise from the same tissue type. Variability in response may arise due to differences in the initial genetic lesions leading to cancer development. Alternatively, susceptibility to viral oncolysis may change during cancer progression. These hypotheses were tested using cells from a transgenic mouse model of prostate cancer infected with vesicular stomatitis virus (VSV). Primary cultures from murine cancers derived from prostate-specific Pten deletion contained a mixture of cells that were susceptible and resistant to VSV. Castration-resistant cancers contained a higher percentage of susceptible cells than cancers from noncastrated mice. These results indicate both susceptible and resistant cells can evolve within the same tumor. The role of Pten deletion was further investigated using clonal populations of murine prostate epithelial (MPE) progenitor cells and tumor-derived Pten(-/-) cells. Deletion of Pten in MPE progenitor cells using a lentivirus vector resulted in cells that responded poorly to interferon and were susceptible to VSV infection. In contrast, tumor-derived Pten(-/-) cel...Continue Reading

References

Nov 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·N C Reich, L M Pfeffer
Dec 23, 1998·Proceedings of the National Academy of Sciences of the United States of America·X WuC L Sawyers
Feb 24, 2001·IUBMB Life·S Balachandran, G N Barber
Sep 13, 2001·Proceedings of the National Academy of Sciences of the United States of America·A PfeiferI M Verma
Feb 22, 2002·Genesis : the Journal of Genetics and Development·Ralf LescheHong Wu
Dec 16, 2004·The Prostate·Wendy W Barclay, Scott D Cramer
Jan 27, 2005·Viral Immunology·Glen N Barber
Apr 29, 2005·Journal of Virology·Guido WollmannAnthony N van den Pol
May 3, 2005·Nature Reviews. Immunology·Leonidas C Platanias
Nov 19, 2005·Nature Reviews. Cancer·Kelley A ParatoJohn C Bell
Jul 4, 2007·The Journal of Clinical Investigation·Isabelle M BerquinYong Q Chen
Jun 23, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Cheng-Chieh TsaiChiou-Feng Lin
Jun 18, 2010·International Journal of Interferon, Cytokine and Mediator Research : IJIM·James M MillerCarol Shoshkes Reiss
Sep 17, 2010·Genes & Development·Michael M Shen, Cory Abate-Shen
Sep 3, 2011·Cancer Gene Therapy·J H StewartD S Lyles
Dec 17, 2011·Human Gene Therapy·Camilo Ayala-BretonKah-Whye Peng
Jan 13, 2012·Journal of Virology·Andrea M MurphyValery Z Grdzelishvili
Feb 9, 2012·Proceedings of the National Academy of Sciences of the United States of America·Scott A EzellPhilip N Tsichlis
Jan 4, 2013·Journal of Virology·Arun AmmayappanStephen J Russell
Jan 23, 2013·Molecular Therapy : the Journal of the American Society of Gene Therapy·Maryam MoussaviPaul S Rennie
Aug 30, 2013·Molecular Therapy : the Journal of the American Society of Gene Therapy·Fethia Ben YebdriRongtuan Lin
Mar 19, 2014·Cell Host & Microbe·John Bell, Grant McFadden

❮ Previous
Next ❯

Citations

Nov 17, 2017·The Journal of General Virology·Sébastien A Felt, Valery Z Grdzelishvili
Aug 4, 2016·Biomarkers in Cancer·Janaina Fernandes
Apr 27, 2018·International Journal of Cancer. Journal International Du Cancer·Carles UrbiolaDorothee von Laer
Sep 14, 2018·Reviews in Medical Virology·Olga V Matveeva, Peter M Chumakov

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.